Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 13,940 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Trial Clear all

Conditions: Locally Recurrent/Metastatic Triple Negative Breast Cancer
Interventions: external beam radiation therapy, cisplatin, Biopsy of Target Tumor; Radiation · Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Compartment Syndrome
Interventions: ECSPRESS catheter with active vacuum; Device
Lead sponsor: Twin Star Medical, Inc.; Industry
Eligibility: 18 Years to 44 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Older Adults, Fall Patients
Interventions: Lateral stepping, Forward walking; Behavioral
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 90 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Pre Diabetes, Polycystic Ovary Syndrome, Obesity Android
Interventions: Liraglutide Pen Injector [Saxenda], Placebo Liraglutide Pen Injector; Drug
Lead sponsor: Woman's; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Diabetic Foot Ulcers
Interventions: AMNIOEXCEL, Standard of Care, Diabetic Foot Ulcers; Other
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 8
States / cities: Phoenix, Arizona • Castro Valley, California • Stockton, California + 5 more

Conditions: Hemophilia A
Interventions: Emicizumab, Factor VIII (FVIII); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 8
States / cities: Santa Monica, California • Washington D.C., District of Columbia • Gainesville, Florida + 5 more

Conditions: Other Cancer, Gastrointestinal Cancer, Thoracic Cancer, Gynecologic Cancer
Interventions: Stakeholder Survey (Control Period), Stakeholder Survey (Intervention Period), Qualitative Interview, SASS Questionnaire, eSyM; Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 42,808 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 6
States / cities: Portland, Maine • Boston, Massachusetts • Lebanon, New Hampshire + 3 more

Conditions: Cognitive Change
Interventions: C1 - Standard Perceptual Learning (SPL), C2 - Long Training (LT), C3 - Short Staircases (SS), C4 - Mixed Difficulty (MD), C5 - Noise Training (NT), C6 - Training with Flankers (TWF), C7 - Parafoveal Training (PT), C8 - Stimulus Variety (SV), C8a - Complex Features (CF), C9 - Exogenous Attention Training (ExAT), C10 - Endogenous Attention Training (EnAT), C11 - Multisensory Facilitation (MF), No Contact Control; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 85 Years
Enrollment: 1,140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Riverside, California • Boston, Massachusetts • Madison, Wisconsin

Conditions: Postoperative Pain
Interventions: Liposomal bupivacaine, Standard of care; Drug · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: Madison, Wisconsin

Conditions: Umbilical Hernia
Interventions: Bupivacaine; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 5 Years to 17 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Oral Complications, Radiation Toxicity
Interventions: filgrastim, palifermin, cyclophosphamide, etoposide, ifosfamide, quality-of-life assessment, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 12 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Gastrointestinal Disease
Interventions: An Enhanced Reminder; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 21 Years to 120 Years
Enrollment: 15,974 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Influenza
Interventions: Nitazoxanide, Placebo; Drug
Lead sponsor: Romark Laboratories L.C.; Industry
Eligibility: 12 Years and older
Enrollment: 1,030 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 34
States / cities: Alabaster, Alabama • Birmingham, Alabama • Hoover, Alabama + 28 more

Conditions: Implant Complication
Interventions: Vertical soft tissue augmentation; Procedure
Lead sponsor: Harvard Medical School (HMS and HSDM); Other
Eligibility: 18 Years to 99 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Tobacco Dependence
Interventions: Direct to Smoker Outreach Program; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Revere, Massachusetts

Conditions: Bipolar Disorder, Cocaine Dependence
Interventions: Lamotrigine, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: 8 weeks of home based use.; Device
Lead sponsor: Michigan State University; Other
Eligibility: 8 Years to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: East Lansing, Michigan

Conditions: Inguinal Hernia
Interventions: Urinary Catheter; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 491 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Epilepsy, Adherence, Medication
Interventions: Automated Digital Reminders, Individualized Adherence Feedback Report, Individual Adherence Feedback Report with Social Norms; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 13 Years to 17 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Gestational Diabetes Mellitus in Pregnancy, Glucose Intolerance During Pregnancy, Non-nutritive Sweeteners Consumption in Pregnancy and/or Lactation
Interventions: NNS Restriction Intervention, Control Intervention; Behavioral
Lead sponsor: George Washington University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 324 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: GERD
Interventions: Aluvra™, Saline; Device · Drug
Lead sponsor: Impleo Medical Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 10
States / cities: Los Angeles, California • Palo Alto, California • Englewood, Colorado + 7 more

Conditions: Breast Cancer, Colon Cancer, Neuropathy
Interventions: topical menthol, placebo lotion; Drug
Lead sponsor: Columbia University; Other
Eligibility: 21 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Constipation, Signs and Symptoms, Digestive Signs and Symptoms, Infrequent or Difficult Evacuation
Interventions: PDS-08, Placebo; Dietary Supplement · Other
Lead sponsor: Seed Health; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Tobacco Dependence
Interventions: Placebo, Nicotine; Drug
Lead sponsor: McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 19
States / cities: Muscle Shoals, Alabama • Oceanside, California • Griffin, Georgia + 16 more

Search by objective public record fields.

Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy

Double Blinded, Randomized Clinical Trial of the Twin Star ECSPRESS Monitoring System for the Reduction of the Incidence of Fasciotomy

Variability of Movement on an Altered Inertial Dynamics Task

Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS

Phase IV Study to Evaluate the Efficacy of AMNIOEXCEL in Diabetic Foot Ulcers

A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors

Symptom Management Implementation of Patient Reported Outcomes in Oncology

Moderators and Mediators of Perceptual Learning

Optimizing Recovery in Abdominoplasty

Analgesic Efficacy After Umbilical Hernia Repair in Children

Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer

Optimizing Gastrointestinal Procedure Appointments

A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza

Vertical Soft Tissue Augmentation With CTG vs ADM

Direct to Smoker Outreach in a Health Care Setting

Lamotrigine add-on Therapy for Bipolar Disorder and Cocaine Dependency

Efficacy of the Apollo System for Children With ADHD

Urinary Retention After Laparoscopic Inguinal Hernia Repair: Comparing the Use of the Intraoperative Urinary Catheter

Behavioral Economics and Adherence in Teens (BEAT!)

Effects of a Non-nutritive Sweetener Reduction Intervention in Pregnancy and Lactation on Maternal and Infant Outcomes

Novel Endoluminal Clinical TreAtment of Reflux

Topical Menthol for the Treatment of Chemotherapy Induced Peripheral Neuropathy

Tolerability and Functional Assessment of a Novel Children's Synbiotic

Study to Determine if a New Nicotine Replacement Therapy Can Safely Help Smokers to Quit Smoking